●重要内容提示: 朱蓉娟持有的公司无限售流通股 1,784 万股于 2026 年 1 月 9 日被广西壮族 自治区南宁市青秀区人民法院司法轮候冻结。 截至本公告披露日，朱蓉娟持有的公司 2,100 万股股份已全部被司法标记、 司法冻结或轮候冻结，占公司总股本的 4.01%。 近日，北海国发川山生物股份有限公司（以下简称"公司"）通过中国证券 登记结算有限公司上海分公司的 PROP 系统查询获悉，公司大股东朱蓉娟持有的 公司 1,784 万股无限售流通股于 2026 年 1 月 9 日被广西壮族自治区南宁市青秀 区人民法院司法轮候冻结。经与大股东朱蓉娟核实，现将司法轮候冻结的具体 情况公告如下： 二、大股东及其一致行动人股份累计被冻结/标记的情况 证券代码：600538 证券简称：国发股份 公告编号：临 2026-003 北海国发川山生物股份有限公司 关于大股东持有的公司部分股份被司法轮候冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至 2026 年 1 月 9 日，大股东及其一致行动人股份累计被司法冻结/标记 ...

证券代码：600538 证券简称：国发股份 公告编号：临2026-002 北海国发川山生物股份有限公司 关于公司董事离任暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 （二）离任对公司的影响 根据《中华人民共和国公司法》（以下简称"《公司法》"）《北海国发川山生物股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，李勇先生辞去公司非独立董事职务不会导致公司董事会成员 人数低于法定最低人数，不影响公司董事会的正常运作，李勇先生的辞任报告自送达公司董事会之日起 生效。截至本公告披露日，李勇先生未持有公司股票，不存在应履行而未履行的公开承诺。辞任后，李 勇先生继续在公司及其控股子公司任职。 二、职工代表董事选举情况 公司于2025年12月18日召开的2025年第三次临时股东大会审议通过了《关于取消监事会的议案》《关于 修订〈公司章程〉的议案》，根据修订后的《公司章程》的有关规定：公司董事会由9名董事组成，其 中职工代表董事的人数为1名。职工代表董事由公司职工通过职工代表大会、职工大会或者其他形式民 ...

证券日报网讯1月12日，国发股份（600538）发布公告称，选举李勇先生为公司第十一届董事会职工代 表董事。 ...

证券代码：600538 证券简称：国发股份 公告编号：临 2026-002 北海国发川山生物股份有限公司 关于公司董事离任暨选举职工代表董事的公告 根据《中华人民共和国公司法》（以下简称"《公司法》"）《北海国发川山生 物股份有限公司章程》（以下简称"《公司章程》"）的相关规定，李勇先生辞去公 司非独立董事职务不会导致公司董事会成员人数低于法定最低人数，不影响公司 1 董事会的正常运作，李勇先生的辞任报告自送达公司董事会之日起生效。截至本 公告披露日，李勇先生未持有公司股票，不存在应履行而未履行的公开承诺。辞 任后，李勇先生继续在公司及其控股子公司任职。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●北海国发川山生物股份有限公司（以下简称"公司"）董事会于 2026 年 1 月 11 日收到公司非独立董事李勇先生的书面辞任报告，因公司治理结构调整， 李勇先生申请辞去公司第十一届董事会非独立董事的职务。 ●公司第一届职工代表大会第二次会议选举李勇先生为公司第十一届董事 会职工代表董事。 一、董事离任情况 姓名 ...

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Core Viewpoint - The announcement details the judicial auction and transfer of shares held by major shareholders of Beihai Guofa Chuanshan Biological Co., Ltd, resulting in a significant reduction in their ownership percentage without triggering mandatory takeover obligations [3][4][6]. Group 1: Shareholder Changes - Major shareholders Zhu Rongjuan and Peng Tao collectively held 22,167,585 shares, representing 4.23% of the total share capital, which were judicially auctioned and transferred to Mojian Changhong Mining Co., Ltd [3][4]. - The ownership percentage of Zhu Rongjuan and associated parties decreased from 10.72% to 6.49% following the transfer [3][6][17]. - The share transfer was a passive reduction due to judicial auction and did not violate any prior commitments or plans [3][4]. Group 2: Impact on Company Management - The equity change will not have a significant adverse impact on the company's management and does not result in a change of the controlling shareholder or actual controller [4][8][19]. - The company will continue to monitor shareholder equity changes and fulfill its information disclosure obligations as required by law [8][19]. Group 3: Judicial Auction Details - The shares were auctioned by the People's Court of Nanning, Guangxi, from November 25 to November 26, 2025, with the auction results published on November 27, 2025 [4][16]. - The court issued a ruling on December 12, 2025, lifting the freeze on the shares held by Zhu Rongjuan and Peng Tao, allowing for the transfer to the buyer [5][16]. Group 4: Future Arrangements - There are no plans for the major shareholders to increase or further reduce their holdings in the company within the next 12 months [15][19]. - The company’s controlling shareholder remains unchanged after the equity change [19].

Core Viewpoint - The announcement indicates a significant change in the shareholding structure of Guofang Co., Ltd. due to a court ruling leading to a judicial auction of shares held by certain individuals [1] Group 1: Shareholding Changes - The court ruling resulted in the judicial auction of 22,167,585 shares, representing 4.23% of the total share capital of Guofang Co., Ltd. [1] - Following this transaction, the combined shareholding of Zhu Rongjuan, Peng Tao, Guangxi Guofang Investment Group Co., Ltd., and Yao Fangyuan decreased from 10.72% to 6.49% [1] - Zhu Rongjuan's shareholding dropped from 7.57% to 4.01%, while Peng Tao's shareholding decreased from 0.66% to 0% [1] Group 2: Control and Ownership - Despite the reduction in shareholding percentages, the controlling shareholder and actual controller of the company remain unchanged [1]

北海国发川山生物股份有限公司 简式权益变动报告书 上市公司名称：北海国发川山生物股份有限公司 股票上市地点：上海证券交易所 股票简称： 国发股份 股票代码： 600538 信息披露义务人：朱蓉娟 住所：南宁市西乡塘区大学东路103号 通讯地址：广西南宁市青秀区金湖北路52-1号东方曼哈顿2402室 信息披露义务人：彭韬 住所：南宁市西乡塘区火炬路11号802室 通讯地址：广西南宁市青秀区金湖北路52-1号东方曼哈顿2402室 1、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司收购管理办法》《公开发行证券公司信息披露内容与格式准则第 15 号——权益变动报告书》及相关的法律、法规编制本报告书。 2、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 3、依据《证券法》《上市公司收购管理办法》《15 号准则》的规定，本报 告书已全面披露了信息披露义务人在北海国发川山生物股份有限公司中拥有权 益的股份变动情况；截至本报告书签署日，除本报告书披露的信息外，上述信 息披露义务人没有通过任何其他方式增加或减少其在北海国 ...

证券代码：600538 证券简称：国发股份 公告编号：临 2026-001 北海国发川山生物股份有限公司 关于大股东及一致行动人部分股份被司法拍卖完成过户 暨权益变动的提示性公告 投资者及其一致行动人（朱蓉娟、彭韬、广西国发投资集团有限公司、姚芳媛）保 证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ●公司大股东朱蓉娟、彭韬合计持有的公司 22,167,585 股无限售流通股股 票（占公司总股本的比例为 4.23%）被司法拍卖非交易过户至墨江县昌宏矿业有 限责任公司名下。本次权益变动前后，公司大股东朱蓉娟及一致行动人持有公司 股份的比例由 10.72%下降至 6.49%； ●本次权益变动系大股东及一致行动人所持公司股份被司法拍卖过户被动 减持所致，不触及强制要约收购义务，本次权益变动不涉及违反已作出的承诺、 意向、计划的情况。 广西壮族自治区南宁市西乡塘区人民法院 2025 年 11 月 25 日 10 时至 2025 年 11 月 26 日 12:10 对公司大股东朱蓉娟及一致行动人彭韬合计持有的 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]